



Marco Bianchi
Senior Vice President
NYSE Liffe US
55 East 52nd Street,
New York, NY 10055
T +1 212 323 8866

By Electronic Mail

March 17, 2014

Ms. Melissa Jurgens
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT
REQUESTED

Re: NYSE Liffe US Submission 2014-106 – Renewal of the Designated Market Maker Program for Eurodollar Futures Contracts.

Dear Ms. Jurgens:

I am a Senior Vice-President of NYSE Liffe US LLC (“NYSE Liffe US” or the “Exchange”). Pursuant to Section 5c(c) of the Commodity Exchange Act, as amended (the “Act”), and U.S. Commodity Futures Trading Commission (the “Commission”) Regulations (the “Regulations”) Section 40.6(a), I enclose a Cover Sheet for NYSE Liffe US Submission 2014-106 and NYSE Liffe US Notice 7/2014 which announces the renewal of the General Designated Market Maker Program (“DMM Program”) in the Eurodollar Futures effective April 1, 2014, through June 30, 2014.

NYSE Liffe US hereby certifies that: (i) the DMM Program for Eurodollar Futures complies with the Act and the Regulations and (ii) a notice and copy of this submission has been concurrently posted on the Exchange’s web site. Additionally, a concise explanation and analysis of the Eurodollar Futures DMM Program and its compliance with applicable provisions of the Act, including core principles and the Regulations, is attached. No substantive opposing views were expressed by members or others with respect to the DMM Program.

If you have any questions, please call me at (212) 323-8866.

Yours Truly,

Marco Bianchi
Enclosures



**FOIA CONFIDENTIAL TREATMENT REQUEST
BY NYSE LIFFE US LLC**

Katherine Cooper
Chief Regulatory Officer
NYSE Liffe U.S.
55 East 52nd Street
New York, NY 10055
T +1 212 323 8870

By Electronic Mail

March 17, 2014

Linda J. Mauldin
Paralegal Specialist
FOIA Compliance Office
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

CONFIDENTIAL TREATMENT
REQUESTED

Re: FOIA Confidential Treatment Request

Dear Ms. Mauldin:

By e-mail dated today, March 17, 2014, NYSE Liffe US LLC ("NYSE Liffe US" or the "Exchange") in connection with NYSE Liffe US Submission 2014-106, voluntarily provided the supplemental information attached.

Pursuant to Commission Regulation § 145.9(d), the Exchange requests confidential treatment of the information attached and this letter on the grounds that disclosure of this information would reveal confidential commercial or financial information of the Exchange. Pursuant to Commission Regulation § 145.9(d)(5) the Exchange requests that confidential treatment of the attached information be maintained until further notice from the Exchange. The Exchange requests that the Commission notify it immediately after receiving any request under the Freedom of Information Act ("FOIA") or any other court order, subpoena or summons for the attached information. The Exchange specifically notes that it does not waive in any manner its rights under Section 8(f) of the Commodity Exchange Act to receive a copy of any subpoena or summons for the attached information prior to the Commission's disclosure of such information pursuant to such subpoena or summons. Finally, the Exchange requests that the Commission notify it in the event that the Commission intends to disclose the attached information to Congress or any federal or state governmental agency or department.

In connection with this request for confidential treatment, and pursuant to Commission Regulation § 40.8, the Exchange is submitting the attached detailed written justification in support of the request for confidential treatment.

If you have any questions, please call me at (212) 323 8870.

Yours truly,

Katherine Cooper
Enclosure